| Code | Description | Claims | Beneficiaries | Total Paid |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
7,441 |
1,328 |
$443K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
3,009 |
884 |
$177K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
4,826 |
950 |
$167K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,788 |
1,234 |
$129K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
395 |
376 |
$129K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,559 |
551 |
$113K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
2,267 |
1,671 |
$108K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
287 |
240 |
$101K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
2,620 |
1,805 |
$96K |
| 80081 |
|
1,206 |
1,175 |
$90K |
| 80053 |
Comprehensive metabolic panel |
13,014 |
11,036 |
$88K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
4,305 |
3,231 |
$88K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
15,969 |
13,368 |
$87K |
| 84443 |
Thyroid stimulating hormone (TSH) |
6,536 |
6,161 |
$82K |
| 99153 |
Mod sedat endo service >5yrs |
1,099 |
763 |
$74K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
2,014 |
1,935 |
$70K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
408 |
374 |
$69K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
2,013 |
1,934 |
$69K |
| 87653 |
|
1,245 |
1,234 |
$46K |
| 99152 |
|
1,410 |
920 |
$46K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
2,152 |
2,079 |
$41K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
245 |
230 |
$41K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
139 |
113 |
$41K |
| 36415 |
Collection of venous blood by venipuncture |
16,108 |
11,401 |
$40K |
| 87507 |
|
102 |
100 |
$37K |
| 70450 |
Computed tomography, head or brain; without contrast material |
800 |
719 |
$34K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
1,168 |
1,144 |
$30K |
| 87088 |
|
4,670 |
4,273 |
$28K |
| 82947 |
|
8,120 |
805 |
$27K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
378 |
364 |
$26K |
| 88342 |
|
360 |
289 |
$23K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
2,640 |
2,277 |
$23K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
1,180 |
379 |
$23K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
3,095 |
2,714 |
$23K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
4,506 |
1,627 |
$21K |
| 71046 |
Radiologic examination, chest; 2 views |
1,819 |
1,616 |
$20K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
691 |
538 |
$20K |
| J2704 |
Injection, propofol, 10 mg |
2,097 |
1,963 |
$20K |
| 80061 |
Lipid panel |
2,563 |
2,485 |
$19K |
| 97161 |
|
386 |
369 |
$19K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
555 |
544 |
$18K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
154 |
147 |
$18K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
2,222 |
1,831 |
$17K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
499 |
476 |
$17K |
| 86141 |
|
2,641 |
2,251 |
$17K |
| 84439 |
|
2,749 |
2,648 |
$16K |
| J7050 |
Infusion, normal saline solution, 250 cc |
5,705 |
3,778 |
$16K |
| 88313 |
|
185 |
143 |
$15K |
| 80306 |
|
1,316 |
1,174 |
$15K |
| 81001 |
|
6,038 |
5,285 |
$15K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
263 |
253 |
$15K |
| 83880 |
|
1,011 |
857 |
$15K |
| 84702 |
|
845 |
691 |
$13K |
| 87660 |
|
582 |
562 |
$13K |
| 84484 |
|
2,406 |
1,523 |
$12K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,488 |
2,367 |
$12K |
| 87186 |
|
1,884 |
1,544 |
$12K |
| 81025 |
|
1,475 |
1,337 |
$12K |
| 87486 |
|
395 |
376 |
$11K |
| 87581 |
|
395 |
376 |
$11K |
| 87510 |
|
582 |
562 |
$11K |
| 87480 |
|
582 |
562 |
$11K |
| 87631 |
|
87 |
84 |
$11K |
| 82607 |
|
1,038 |
1,005 |
$11K |
| 97116 |
|
559 |
153 |
$10K |
| 82553 |
|
1,858 |
1,415 |
$10K |
| 90870 |
|
40 |
13 |
$10K |
| 87077 |
|
1,776 |
1,450 |
$9K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,074 |
489 |
$9K |
| 73030 |
|
666 |
503 |
$9K |
| 82728 |
|
905 |
873 |
$9K |
| 83690 |
|
1,507 |
1,330 |
$9K |
| 87641 |
|
359 |
329 |
$8K |
| 83605 |
|
1,624 |
1,291 |
$8K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
608 |
532 |
$8K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
3,317 |
2,708 |
$8K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
558 |
486 |
$8K |
| 72100 |
|
537 |
493 |
$8K |
| 85730 |
|
1,977 |
1,697 |
$8K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
109 |
104 |
$8K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
43 |
40 |
$8K |
| 82550 |
|
2,147 |
1,620 |
$7K |
| 85610 |
|
2,519 |
1,988 |
$7K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,921 |
1,728 |
$7K |
| 88304 |
|
210 |
192 |
$7K |
| 83735 |
|
2,167 |
1,814 |
$7K |
| 84481 |
|
538 |
521 |
$7K |
| 73562 |
|
329 |
264 |
$6K |
| 84145 |
|
519 |
436 |
$6K |
| 82950 |
|
1,244 |
1,224 |
$6K |
| 97014 |
|
450 |
116 |
$6K |
| 73630 |
|
412 |
337 |
$5K |
| G0283 |
Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care |
417 |
122 |
$5K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,514 |
1,321 |
$5K |
| 97016 |
|
328 |
93 |
$4K |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
833 |
780 |
$4K |
| 82746 |
|
381 |
374 |
$4K |
| A4218 |
Sterile saline or water, metered dose dispenser, 10 ml |
3,847 |
2,489 |
$4K |
| 83525 |
|
518 |
399 |
$4K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
132 |
130 |
$4K |
| 83540 |
|
766 |
742 |
$4K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
431 |
349 |
$4K |
| 85380 |
|
483 |
420 |
$3K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
671 |
551 |
$3K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
270 |
196 |
$3K |
| 88142 |
|
156 |
154 |
$3K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
261 |
163 |
$3K |
| 83970 |
|
134 |
123 |
$3K |
| 85652 |
|
1,186 |
1,044 |
$3K |
| 84403 |
|
130 |
128 |
$3K |
| 73610 |
|
196 |
161 |
$3K |
| 83550 |
|
388 |
379 |
$3K |
| 87640 |
|
357 |
329 |
$3K |
| 99215 |
Prolong outpt/office vis |
210 |
70 |
$2K |
| 87070 |
|
404 |
344 |
$2K |
| 73130 |
|
144 |
114 |
$2K |
| 76830 |
Ultrasound, transvaginal |
27 |
26 |
$2K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
168 |
94 |
$2K |
| 82570 |
|
477 |
452 |
$2K |
| 84270 |
|
93 |
92 |
$2K |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
348 |
276 |
$2K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
70 |
69 |
$2K |
| 84550 |
|
531 |
506 |
$2K |
| 74178 |
|
12 |
12 |
$2K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
649 |
529 |
$2K |
| 86038 |
|
137 |
135 |
$1K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
29 |
26 |
$1K |
| 83516 |
|
147 |
75 |
$1K |
| 73560 |
|
91 |
74 |
$1K |
| 86769 |
|
44 |
43 |
$1K |
| 73502 |
|
81 |
68 |
$1K |
| 84703 |
|
180 |
175 |
$1K |
| 86850 |
|
184 |
169 |
$1K |
| 73564 |
|
71 |
52 |
$1K |
| 87040 |
|
164 |
73 |
$1K |
| 86677 |
|
82 |
77 |
$1K |
| 85027 |
|
510 |
428 |
$1K |
| 73110 |
|
66 |
52 |
$1K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
235 |
204 |
$1K |
| 71045 |
Radiologic examination, chest; single view |
214 |
166 |
$981.32 |
| 82951 |
|
74 |
74 |
$964.06 |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
14 |
14 |
$960.91 |
| 87899 |
|
68 |
68 |
$914.81 |
| 76937 |
|
55 |
40 |
$869.54 |
| 93971 |
|
17 |
12 |
$846.19 |
| 82670 |
|
37 |
36 |
$839.40 |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
60 |
25 |
$810.49 |
| 20610 |
|
16 |
12 |
$796.57 |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
24 |
18 |
$787.02 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
948 |
816 |
$784.87 |
| 83520 |
|
57 |
55 |
$777.00 |
| 97597 |
|
60 |
26 |
$737.63 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
307 |
242 |
$716.04 |
| 72040 |
|
47 |
43 |
$638.80 |
| 85007 |
|
792 |
664 |
$633.74 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
399 |
305 |
$628.18 |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
13 |
12 |
$623.70 |
| 96361 |
Intravenous infusion, hydration; each additional hour |
402 |
344 |
$621.95 |
| 83001 |
|
30 |
30 |
$598.85 |
| 82677 |
|
24 |
24 |
$594.95 |
| 82248 |
|
131 |
113 |
$581.30 |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
57 |
54 |
$571.60 |
| 80069 |
|
131 |
113 |
$556.20 |
| 82150 |
|
84 |
84 |
$510.86 |
| 82105 |
|
27 |
27 |
$468.63 |
| J2060 |
Injection, lorazepam, 2 mg |
327 |
271 |
$446.65 |
| 84156 |
|
164 |
148 |
$443.56 |
| 86376 |
|
38 |
37 |
$441.49 |
| 73080 |
|
19 |
16 |
$436.30 |
| 99053 |
|
771 |
694 |
$417.11 |
| 84482 |
|
29 |
27 |
$390.72 |
| 82952 |
|
99 |
80 |
$384.75 |
| 86336 |
|
24 |
24 |
$383.48 |
| 88300 |
|
34 |
29 |
$339.38 |
| 80050 |
General health panel |
149 |
146 |
$315.29 |
| 84630 |
|
36 |
28 |
$304.73 |
| 36591 |
|
96 |
78 |
$258.20 |
| Q0092 |
Set-up portable x-ray equipment |
197 |
162 |
$217.07 |
| 84144 |
|
14 |
14 |
$209.60 |
| R0070 |
Transportation of portable x-ray equipment and personnel to home or nursing home, per trip to facility or location, one patient seen |
197 |
162 |
$205.48 |
| 82542 |
|
12 |
12 |
$201.96 |
| 82627 |
|
12 |
12 |
$198.70 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
235 |
201 |
$189.38 |
| 86901 |
|
90 |
48 |
$180.52 |
| 83090 |
|
13 |
13 |
$169.54 |
| 83615 |
|
27 |
27 |
$161.04 |
| 86664 |
|
12 |
12 |
$153.62 |
| 82043 |
|
30 |
30 |
$141.97 |
| J0706 |
Injection, caffeine citrate, 5 mg |
69 |
15 |
$132.37 |
| 86663 |
|
12 |
12 |
$131.85 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
34 |
27 |
$127.09 |
| 82784 |
|
22 |
13 |
$123.96 |
| 84100 |
|
44 |
34 |
$100.76 |
| 86900 |
|
52 |
25 |
$99.60 |
| 94760 |
|
95 |
83 |
$96.39 |
| J7070 |
Infusion, d5w, 1000 cc |
107 |
86 |
$96.34 |
| 82800 |
|
13 |
12 |
$93.44 |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
35 |
33 |
$78.24 |
| 86430 |
|
15 |
15 |
$76.45 |
| 87081 |
|
13 |
12 |
$60.80 |
| 86592 |
|
16 |
15 |
$58.15 |
| 87205 |
|
14 |
13 |
$42.66 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
49 |
41 |
$41.41 |
| Q9965 |
Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml |
13 |
12 |
$40.07 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
149 |
144 |
$28.97 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
12 |
12 |
$27.25 |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
13 |
13 |
$26.66 |
| 81003 |
|
13 |
12 |
$4.35 |
| A6235 |
Hydrocolloid dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing |
18 |
13 |
$0.65 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
22 |
14 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
23 |
15 |
$0.00 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
84 |
52 |
$-43.27 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
29 |
24 |
$-661.99 |